Semaglutide treatment restored GLP-1 levels, regulated Socs3 expression in ARC and improved leptin sensitivity and the hypothalamic anorexigenic signaling (POMC/MC4R) for obesity control in these obese mice [131]. This evidence concerns the gene SOCS3 and obesity due to melanocortin 4 receptor deficiency.